Laboratorio de Aminoácidos Excitadores, Instituto Nacional de Neurología y Neurocirugía - S.S.A., México City, Mexico.
Free Radic Biol Med. 2012 Sep 1;53(5):1024-40. doi: 10.1016/j.freeradbiomed.2012.06.040. Epub 2012 Jul 8.
Pharmacological activation at the basal ganglia of the transcription factor Nrf2, guardian of redox homeostasis, holds a strong promise for the slow progression of Parkinson's disease (PD). However, a potent Nrf2 activator in the brain still must be found. In this study, we have investigated the potential use of the antioxidant compound S-allyl cysteine (SAC) in the activation of Nrf2 in 6-hydoxydopamine (6-OHDA)-intoxicated rats. In the rat striatum, SAC by itself promoted the Nrf2 dissociation of Keap-1, its nuclear translocation, the subsequent association with small MafK protein, and further binding of the Nrf2/MafK complex to ARE sequence, as well as the up-regulation of Nrf2-dependent genes encoding the antioxidant enzymes HO-1, NQO-1, GR, and SOD-1. In vivo and in vitro experiments to identify signaling pathways activated by SAC pointed to Akt as the most likely kinase participating in Nrf2 activation by SAC. In PC12 cells, SAC stimulated the activation of Akt and ERK1/2 and inhibited JNK1/2/3 activation. In the rat striatum, the SAC-induced activation of Nrf2 is likely to contribute to inhibit the toxic effects of 6-OHDA evidenced by phase 2 antioxidant enzymes up-regulation, glutathione recovery, and attenuation of reactive oxygen species (ROS), nitric oxide (NO), and lipid peroxides formation. These early protective effects correlated with the long-term preservation of the cellular redox status, the striatal dopamine (DA) and tyrosine hydroxylase (TH) levels, and the improvement of motor skills. Therefore, this study indicates that, in addition to direct scavenging actions, the activation of Nrf2 by SAC might confer neuroprotective responses through the modulation of kinase signaling pathways in rodent models of PD, and suggests that this antioxidant molecule may have a therapeutic value in this human pathology.
在基底神经节激活转录因子 Nrf2,作为氧化还原平衡的守护者,对于帕金森病(PD)的缓慢进展具有巨大的应用前景。然而,仍需要在大脑中找到一种有效的 Nrf2 激活剂。在本研究中,我们研究了抗氧化化合物 S-烯丙基半胱氨酸(SAC)在 6-羟基多巴胺(6-OHDA)中毒大鼠中激活 Nrf2 的潜在用途。在大鼠纹状体中,SAC 本身可促进 Nrf2 与 Keap-1 的解离、核转位、随后与小 MafK 蛋白的结合,以及 Nrf2/MafK 复合物与 ARE 序列的结合,进一步上调 Nrf2 依赖性基因,编码抗氧化酶 HO-1、NQO-1、GR 和 SOD-1。体内和体外实验鉴定 SAC 激活的信号通路表明 Akt 是最有可能参与 SAC 激活 Nrf2 的激酶。在 PC12 细胞中,SAC 可刺激 Akt 和 ERK1/2 的激活,并抑制 JNK1/2/3 的激活。在大鼠纹状体中,SAC 诱导的 Nrf2 激活可能有助于抑制 6-OHDA 的毒性作用,表现为上调 II 相抗氧化酶、恢复谷胱甘肽以及减少活性氧(ROS)、一氧化氮(NO)和脂质过氧化物的形成。这些早期的保护作用与细胞氧化还原状态、纹状体多巴胺(DA)和酪氨酸羟化酶(TH)水平的长期维持以及运动技能的改善相关。因此,本研究表明,除了直接清除作用外,SAC 通过调节帕金森病啮齿动物模型中的激酶信号通路激活 Nrf2,可能赋予其神经保护反应,并提示这种抗氧化分子在这种人类疾病中具有治疗价值。